Medindia LOGIN REGISTER
Medindia
Advertisement

AstraZeneca/Targacept's TC-5214 Will Become Decision Resources' Proprietary Clinical Gold Standard In 2013 Through 2018 For Treatment Resistant Depression

Monday, April 19, 2010 General News
Advertisement
Surveyed U.S. and European Physicians Indicate that Effect on Depressive Symptoms is the Most Important Drug Attribute They Consider When Prescribing for the Disorder, According to a New Report from Decision Resources
Advertisement

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

[email protected]

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close